Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 11Other neoplasm 4

Conditions

Precancerous Conditions 145Lymphoma 34Leukemia 32Multiple Myeloma 31Neoplasms, Plasma Cell 30Monoclonal Gammopathy of Undetermined Significance 30Lymphoma, Non-Hodgkin 29Lymphoma, Mantle-Cell 29Lymphoma, Large-Cell, Immunoblastic 29Lymphoma, Large B-Cell, Diffuse 29Lymphoma, Follicular 29Leukemia, Lymphocytic, Chronic, B-Cell 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Lymphoma, B-Cell, Marginal Zone 28Burkitt Lymphoma 28Immunoglobulin Light-chain Amyloidosis 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 26Hodgkin Disease 26Waldenstrom Macroglobulinemia 25Myeloproliferative Disorders 25Immunoblastic Lymphadenopathy 25Myelodysplastic Syndromes 24Lymphoma, Large-Cell, Anaplastic 24Leukemia, Hairy Cell 24Thrombocythemia, Essential 23Primary Myelofibrosis 23Leukemia, Myeloid, Acute 23Leukemia, Large Granular Lymphocytic 23Lymphoma, T-Cell, Cutaneous 22Leukemia, Prolymphocytic 22

Interventions

tirbanibulin 1BF-200 ALA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Keratosis × Other neoplasm × Clear all
NCT06135415 2026-03-25

TirbAKare

Almirall, S.A.

Phase 3 Completed
280 enrolled
DermatologicOther neoplasm

Keratosis, Neoplasms, Precancerous Conditions, Keratosis, Actinic

NCT05060237 2024-10-17

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Biofrontera Bioscience GmbH

Phase 1 Completed
112 enrolled 21 charts
DermatologicOther neoplasm

Keratosis, Precancerous Conditions, Skin Diseases, Keratosis, Actinic

NCT03285477 2021-04-13

AK003

Almirall, S.A.

Phase 3 Completed
351 enrolled 17 charts
DermatologicOther neoplasm

Keratosis, Neoplasms, Precancerous Conditions, Skin Diseases, Keratosis, Actinic

NCT03285490 2021-03-10

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)

Almirall, S.A.

Phase 3 Completed
351 enrolled 16 charts
DermatologicOther neoplasm

Keratosis, Neoplasms, Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡